{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T03:13:15Z","timestamp":1724469195236},"reference-count":23,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Patient-reported outcome instruments are key in assessing COVID-19\u2013related symptoms and associated burden. However, a valid and reliable instrument to assess symptom severity and progression among outpatients with COVID-19 is not yet available.<\/jats:p><\/jats:sec>Objectives<\/jats:title>To assess the extent to which the Symptoms Evolution of COVID-19 (SE-C19) instrument is valid, reliable, and able to detect symptom changes in outpatients with COVID-19, as well as to establish a definition of symptom resolution.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>In this diagnostic\/prognostic study, psychometric properties of SE-C19 were assessed in participants recruited into an ongoing, adaptive, phase 1\/2\/3, randomized, double-blind, placebo-controlled clinical trial, during 2020 to 2022. Adult outpatients with symptomatic COVID-19 were randomized 1:1:1 to receive 2.4 g or 8.0 g intravenous casirivimab and imdevimab or placebo, in outpatient centers at 114 sites, from 2 countries (US and Mexico).<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Reliability, validity, and sensitivity to change of the SE-C19 were assessed. SE-C19 and Patient Global Impression of Severity (PGIS) were administered daily from predose at day 1 to day 29.<\/jats:p><\/jats:sec>Results<\/jats:title>Analysis was conducted on 657 adult outpatients (342 female patients [52.1%], 562 White patients [85.5%]), and 337 non-Hispanic patients [51.3%]. At baseline, patients reported a mean (SD) of 6.6 (3.9) symptoms (ie, rated as at least mild)<\/jats:italic> with a mean (SD) of 3.8 (3.3) of these symptoms being rated as moderate or severe. Stable patients according to PGIS showed scores with intraclass correlation values indicating moderate-to-good test-retest reliability (ie, 0.50-0.90). At baseline, 20 item scores (87%) varied significantly across PGIS-defined groups, supporting the validity of the SE-C19. A symptom-resolution end point was defined after excluding the item sneezing due to its low ability to discriminate severity levels, and excluding confusion, rash, and vomiting, due to their low prevalence in this population. Symptom resolution required complete absence of all remaining items, except cough, fatigue, and headache, which could be mild or moderate in severity. A total of 19 of 23 items from the SE-C19 instrument were identified as valid and reliable to measure disease-related symptoms in outpatients with COVID-19.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This study identified 19 items that are valid and reliable to measure disease-related symptoms in outpatients with COVID-19, and proposed a definition of symptom resolution for potential use in future clinical trials.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.39053","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T15:30:49Z","timestamp":1666971049000},"page":"e2239053","source":"Crossref","is-referenced-by-count":2,"title":["Reliability and Validity of an Instrument of COVID-19 Patient-Reported Symptoms in Outpatients"],"prefix":"10.1001","volume":"5","author":[{"given":"Diana","family":"Rofail","sequence":"first","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc, Sleepy Hollow, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pip","family":"Griffiths","sequence":"additional","affiliation":[{"name":"IQVIA France, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulio","family":"Flore","sequence":"additional","affiliation":[{"name":"IQVIA, Amsterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Hussein","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc, Sleepy Hollow, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumathi","family":"Sivapalasingam","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc, Sleepy Hollow, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna J.","family":"Podolanczuk","sequence":"additional","affiliation":[{"name":"Pulmonary Critical Care Medicine, Weill Cornell Medical College, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Maria","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"IQVIA, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera","family":"Mastey","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc, Sleepy Hollow, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chad","family":"Gwaltney","sequence":"additional","affiliation":[{"name":"Gwaltney Consulting, Westerly, Rhode Island"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2022,10,28]]},"reference":[{"issue":"30","key":"zoi221105r1","doi-asserted-by":"publisher","first-page":"993","DOI":"10.15585\/mmwr.mm6930e1","article-title":"Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network\u2014United States, March-June 2020.","volume":"69","author":"Tenforde","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"zoi221105r4","doi-asserted-by":"publisher","first-page":"6208","DOI":"10.1038\/s41467-020-20053-y","article-title":"Longitudinal symptom dynamics of COVID-19 infection.","volume":"11","author":"Mizrahi","year":"2020","journal-title":"Nat Commun"},{"issue":"2","key":"zoi221105r5","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab007","article-title":"The clinical course of COVID-19 in the outpatient setting: a prospective cohort study.","volume":"8","author":"Blair","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"zoi221105r6","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/irv.v15.3","article-title":"Symptoms and recovery among adult outpatients with and without COVID-19 at 11 healthcare facilities-July 2020, United States.","volume":"15","author":"Fisher","year":"2021","journal-title":"Influenza Other Respir Viruses"},{"issue":"7","key":"zoi221105r7","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa271","article-title":"Symptoms of COVID-19 outpatients in the United States.","volume":"7","author":"Pullen","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"zoi221105r8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-044154","article-title":"Description of symptom course in a telemedicine monitoring clinic for acute symptomatic COVID-19: a retrospective cohort study.","volume":"11","author":"O\u2019Keefe","year":"2021","journal-title":"BMJ Open"},{"issue":"3","key":"zoi221105r9","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.dsx.2021.04.007","article-title":"Long COVID: an overview.","volume":"15","author":"Raveendran","year":"2021","journal-title":"Diabetes Metab Syndr"},{"issue":"10250","key":"zoi221105r10","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S0140-6736(20)31724-4","article-title":"Patient-reported outcomes: central to the management of COVID-19.","volume":"396","author":"Aiyegbusi","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"zoi221105r11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s41687-022-00448-9","article-title":"Development and content validation of the Symptoms Evolution of COVID-19: a patient-reported electronic daily diary in clinical and real-world studies.","volume":"6","author":"Rofail","year":"2022","journal-title":"J Patient Rep Outcomes"},{"issue":"23","key":"zoi221105r12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108163","article-title":"REGEN-COV antibody combination and outcomes in outpatients with Covid-19.","volume":"385","author":"Weinreich","year":"2021","journal-title":"N Engl J Med"},{"issue":"20","key":"zoi221105r13","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"2","key":"zoi221105r15","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/j.1524-4733.2005.04054.x","article-title":"Principles of good practice for the translation and cultural adaptation process for Patient-Reported Outcomes (PRO) measures: report of the ISPOR Task Force for Translation and Cultural Adaptation.","volume":"8","author":"Wild","year":"2005","journal-title":"Value Health"},{"issue":"1","key":"zoi221105r16","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1067\/mob.2003.379","article-title":"Validation of two global impression questionnaires for incontinence.","volume":"189","author":"Yalcin","year":"2003","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"zoi221105r17","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","article-title":"Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations.","volume":"9","author":"Dworkin","year":"2008","journal-title":"J Pain"},{"issue":"2","key":"zoi221105r18","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1037\/0033-2909.86.2.420","article-title":"Intraclass correlations: uses in assessing rater reliability.","volume":"86","author":"Shrout","year":"1979","journal-title":"Psychol Bull"},{"issue":"2","key":"zoi221105r19","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jcm.2016.02.012","article-title":"A guideline of selecting and reporting intraclass correlation coefficients for reliability research.","volume":"15","author":"Koo","year":"2016","journal-title":"J Chiropr Med"},{"issue":"1","key":"zoi221105r20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11136-017-1616-3","article-title":"Moving from significance to real-world meaning: methods for interpreting change in clinical outcome assessment scores.","volume":"27","author":"Coon","year":"2018","journal-title":"Qual Life Res"},{"issue":"Pt 1","key":"zoi221105r21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1348\/014466506X96931","article-title":"An introduction to the Rasch measurement model: an example using the Hospital Anxiety and Depression Scale (HADS).","volume":"46","author":"Pallant","year":"2007","journal-title":"Br J Clin Psychol"},{"key":"zoi221105r22","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/BF02293814","article-title":"A rating formulation for ordered response categories.","volume":"43","author":"Andrich","year":"1978","journal-title":"Psychometrika"},{"issue":"24","key":"zoi221105r23","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1001\/jama.2020.23910","article-title":"Hospital readmission is common among COVID-19 survivors.","volume":"324","author":"Kuehn","year":"2020","journal-title":"JAMA"},{"key":"zoi221105r2","unstructured":"Food and Drug Administration. Assessing COVID-19\u2013related symptoms in outpatient adult and adolescent subjects in clinical trials of drugs and biological products for COVID-19 prevention or treatment. Updated September 2020. Accessed July 6, 2022. https:\/\/www.fda.gov\/media\/142143\/download"},{"key":"zoi221105r3","unstructured":"US Centers for Disease Control and Prevention. Symptoms of coronavirus. Updated March 22, 2022. Accessed July 6, 2022. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/symptoms-testing\/symptoms.html"},{"key":"zoi221105r14","unstructured":"Food and Drug Administration. FDA patient-focused drug development guidance series for enhancing the incorporation of the patient\u2019s voice in medical product development and regulatory decision making. Updated June 29, 2020. Accessed July 6, 2022. https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2797910\/rofail_2022_oi_221105_1666297506.20324.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T15:30:53Z","timestamp":1666971053000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2797910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,28]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.39053","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,28]]}}}